Nanjing Carephar Shenghui Pharmaceutical

Nanjing Carephar Shenghui Pharmaceutical is a clinical-stage biotechnology company based in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-value targets in the fields of immunology, oncology, and metabolic diseases, with a particular emphasis on kinase inhibitors. Its lead candidate, CP-001, is a highly selective TYK2 inhibitor currently being evaluated for the treatment of psoriasis and other autoimmune conditions. Carephar leverages its proprietary drug discovery platform to advance a robust pipeline of candidates, including JAK1 and URAT1 inhibitors. The company aims to provide effective and affordable treatment options for patients with chronic inflammatory and metabolic disorders.